LUGANO-SINGAPORE – Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers will report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
“Adjuvant endocrine treatment such as tamoxifen prevents recurrence and improves absolute survival by 5–10% in patients with oestrogen receptor (ER) positive breast cancer, especially when taken long term (5–10 years),” said lead author Dr Wahyu Wulaningsih, research associate, MRC Unit for Lifelong Health and Ageing at University College London, UK and co-founder of Philippine and Indonesian Scholars (PILAR) Research and Education.
“A substantial proportion of patients who start this treatment do not complete it,” continued Wulaningsih. “There is evidence that failure to take the medicine could lead to worse survival. We therefore investigated the reasons for non-adherence so that targeted strategies could be developed.”
The study included 5,544 women with ER positive breast cancer who collected at least one prescription of aromatase inhibitors or tamoxifen and had five years of follow up data. Women were identified and prescription information was obtained from the regional registers of Uppsala-Örebro, Stockholm-Gotland, and Northern Sweden which cover around 60% of the Swedish population. The data was linked to Swedish national registers with information about factors which could influence adherence. Adherence was calculated from the drugs dispensed – patients were classified as non-adherent if they received less than 80% of the drugs needed over five years.
During the five years, 20% of the women became non-adherent. In the multivariable analysis the strongest independent predictors of non-adherence were younger age, previous use of HRT, marital status, and socioeconomic status (measured by type of employment).
Women less than 50 years of age were 50% more likely to be non-adherent than 50–65 year olds, with 5% of all non-adherent cases attributable to being in the younger age group. Women who had used HRT were 57% more likely to be non-adherent than those who had not. Unmarried women were 33% more likely to be non-adherent than married women. Regarding employment, unemployed women had 60% higher odds to be non-adherent compared to blue collar workers. White collar women were slightly less likely to adhere to endocrine treatment compared to blue collar patients, but the absolute difference was negligible.
Wulaningsih said: “A proportion of breast cancer patients of reproductive age may be concerned about the potential impact of endocrine treatment on fertility which could explain why they are more likely to stop taking the drugs. Women who wish to have children after a breast cancer diagnosis need more information about their treatment options.”
“Research is needed to find out if there are any biological differences in women exposed to HRT before undergoing endocrine treatment for breast cancer,” continued Wulaningsih. “It could be that they are more predisposed to side effects from endocrine treatment. Personalised approaches may improve adherence in these patients by, for example, tailoring the dosage.”
Wulaningsih speculated that unmarried patients might have less social and emotional support to continue taking endocrine therapy.
She said: “Our study identified subgroups of patients who can be targeted with information on the benefits and consequences of endocrine treatment when it is first prescribed and at subsequent visits. Patient support groups could be strengthened, or developed, to help patients overcome the barriers to continuing treatment. Improving adherence should lead to better outcomes for these patients.”
Commenting on the findings, Dr Lim Siew Eng, senior consultant, Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), said: “Nonadherence to oral endocrine therapy is associated with higher recurrence rates, and is the most important modifiable risk factor that can affect breast cancer outcomes.”
She continued: “In this large study, mainly socioeconomic factors and not disease nor treatment factors were identified as risks for nonadherence. Pre-diagnostic use of HRT was also identified. These risk factors could pinpoint certain groups in which stricter compliance monitoring and better management of side effects might improve adherence rates.
Notes to Editors
This study is a collaborative work involving researchers from King’s College London, Karolinska Institutet, Örebro University and Uppsala-Örebro Regional Cancer Center.
- Abstract 62O_PR – ‘Non-adherence to adjuvant endocrine treatment and its determinants among early stage breast cancer patients’ will be presented by Wulan Wulaningsih during the Proffered Paper session ‘Breast cancer’: on Saturday, 17 December, 16:30 – 18:15 (SGT).
Other abstracts of interest on breast cancer recurrence:
Abstract 64O_PR – ‘High mammographic breast density predicts locoregional recurrence after modified radical mastectomy for invasive breast cancer: A case-control study’ will be presented by Y-S Huang during the Proffered Paper session ‘Breast cancer’: on Saturday, 17 December, 16:30 – 18:15 (SGT).
Abstract 99O_PR – ‘Prediction of relapse in patients with locally advanced breast cancer after neoadjuvant treatment’ will be presented by O. Aseyev during the Proffered Paper session ‘Breast cancer’: on Saturday, 17 December, 16:30 – 18:15 (SGT).
Abstract 117PD_PR – ‘Survival benefit of surgical removal for the primary tumour in stage IV breast cancer patients’ will be presented by H. Kim during the Poster Discussion session ‘Breast cancer’: on Monday, 19 December, 09:00 – 10:00 (SGT).
This press release contains information provided by the authors of the highlighted abstracts and reflects the content of those abstracts. It does not necessarily reflect the views or opinions of ESMO and ESMO cannot be held responsible for the accuracy of the data. Commentators quoted in the press release have filled in the ESMO disclosure form in accordance with the ESMO Declaration of Interests policy.
About the European Society for Medical Oncology
ESMO is the leading professional organisation for medical oncology. Comprising more than 15,000 oncology professionals from over 130 countries, we are the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evolving professional environment.
Founded in 1975, ESMO has European roots and a global reach: we welcome oncology professionals from around the world. We are a home for all oncology stakeholders, connecting professionals with diverse expertise and experience. Our educational and information resources support an integrated, multi-professional approach to cancer treatment. We seek to erase boundaries in cancer care as we pursue our mission across oncology, worldwide.
Follow the conference on Twitter by using the hashtag #ESMOAsia16